Adamas Pharmaceuticals Inc
A Financial Overview of Supernus Pharmaceuticals in September
In Q2 2018, Supernus Pharmaceuticals (SUPN) reported net revenues of $99.5 million compared to $75.8 million in Q2 2017.
Supernus Pharmaceuticals Garners 89% ‘Buy’ Ratings in September
Of the nine analysts tracking Supernus Pharmaceuticals (SUPN), three recommended a “strong buy” while five analysts recommended a “buy.”
Why Reata Pharmaceuticals’ Stock Price Is Skyrocketing Today
Today, Reata Pharmaceuticals is trading at a stock price of $75.00, which represents a ~61.67% hike from yesterday’s close of $46.4.
Why Axovant Sciences Stock Rose in Week Ended June 8
On June 6, Axovant Sciences entered into an agreement to develop and sell Oxford BioMedica’s OXB-102 for the treatment of Parkinson’s disease.